Key result
Novel antiplatelet therapies targeting primary platelet adhesion-signaling receptors like GPIb-IX-V and GPVI may improve antithrombosis with minimal bleeding compared to current clinical drugs.
Answers are grounded in this paper and cite their sources.
This review highlights the potential of targeting primary platelet adhesion-signaling receptors (GPIb-IX-V and GPVI) to develop novel antiplatelet therapies that minimize bleeding risks.
An unresolved problem with clinical use of antiplatelet therapy is that a significant number of individuals either still get thrombosis or run the risk of life-threatening bleeding. Antiplatelet drugs are widely used clinically, either chronically for people at risk of athero/thrombotic disease or to prevent thrombus formation during surgery. However, a subpopulation may be resistant to standard doses, while the platelet targets of these drugs are also critical for the normal hemostatic function of platelets. In this review, we will briefly examine current antiplatelet therapy and existing targets while focusing on new potential approaches for antiplatelet therapy and improved monitoring of effects on platelet reactivity in individuals, ultimately to improve antithrombosis with minimal bleeding. Primary platelet adhesion-signaling receptors, glycoprotein (GP)Ib-IX-V and GPVI, that bind von Willebrand factor/collagen and other prothrombotic factors are not targeted by drugs in clinical use, but they are of particular interest because of their key role in thrombus formation at pathological shear.
No takes yet. Share an insight, caveat, or question.
Metharom et al. (2015) conducted a review in Athero/thrombotic disease. Antiplatelet therapy was evaluated. Novel antiplatelet therapies targeting primary platelet adhesion-signaling receptors like GPIb-IX-V and GPVI may improve antithrombosis with minimal bleeding compared to current clinical drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: